Analyzing thiol-dependent redox networks in the presence of methylene blue and other antimalarial agents with RT-PCR-supported in silico modeling

Bioinformatics and Biology Insights

Volumn 6, Issue , 2012, Pages 287-302

  Zirkel, J ^a,c   Cecil, A ^a   Schafer F ^a,c   Rahlfs, S ^b   Ouedraogo, A ^c   Xiao, K ^a   Sawadogo, S ^c   Coulibaly, B ^c   Becker, K ^b   Dandekar, T ^a,d  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c CENTRE DE RECHERCHE EN SANTÉ DE NOUNA   (Burkina Faso)

^d EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

Combination therapy; Drug; Elementary mode analysis; Malaria; Metabolic flux; Methylene blue; Pathway; Resistance

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; GLUTAREDOXIN; GLUTATHIONE PEROXIDASE; LACTATE DEHYDROGENASE; METHYLENE BLUE; PYRIMETHAMINE PLUS SULFADOXINE; SULFADOXINE;

ANTIMALARIAL ACTIVITY; ARTICLE; BIOCHEMISTRY; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; NONHUMAN; OXIDATION REDUCTION REACTION; PLASMODIUM FALCIPARUM; POLYMERIZATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOICHIOMETRY; UPREGULATION;

PLASMODIUM FALCIPARUM;

EID: 84870904803     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.4137/BBI.S10193     Document Type: Article

References (48)

1. Greenwood BM, Bojang K, Whitty JM, Targett GA. Malaria. Lancet. 2005;365:1487-98.
2. Trape JF. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg. 2001:12-7.
3. Trape JF, Pison G, Spiegel A, Enel C, Rogier C. Combating malaria in Africa. Trends Parasitol. 2002:2242-30.
4. Kouyaté B, Sie A, Yé M, De Allegri M, Müller O. The great failure of malaria control in Africa: a district perspective from Burkina Faso. PloS Med. 2007:127.
5. World Health Organization/UNICEF. World Malaria Report 2008. Available at: http://www.who.int/malaria/publications/atoz/9789241563697/en/index.html/.
6. Sachs JD. Achieving the millennium development goals-the case of malaria. N Engl J Med. 2005:115-7.
7. Osorio L, Gonzalez I, Olliaro P, Taylor WR. Artemisinin-based combination therapy for uncomplicated plasmodium falciparum malaria in Colombia. Malar J. 2007:25.
8. International Artemisinin Study Group. Artesunate combinations for treating uncomplicated malaria: a prospective individual patient data meta-analysis. Lancet. 2004:9-17.
9. Sutherland CJ, Ord R, Dunyo S, et al. Reduction of malaria transmission to anopheles mosquitoes with a six-dose regimen of co-artemether. PLoS Med. 2005:e92.
10. Duffy PE, Sibley CH. Are we loosing artemisinin combination therapy already? Lancet. 2005:1908-9.
11. Jambou R, Legrand E, Niang M, et al. Resistance of plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet. 2005:1960-3.
12. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Artemisinin resistance in Cambodia 1 (ARC1) study consortium. N Engl J Med. 2008:2619-20.
13. Bloland PB, Ettling M, Meek S. Combination therapy for malaria in Africa: hype or hope? Bull World Health Organ. 2000:1387-88.
14. Garner P, Graves PM. The benefits of artemisinin combination therapy for malaria extend beyond the individual patient. PLoS Med. 2005:e105.
15. Wiseman V, Kim M, Mutabingwa TK, Whitty CJM. Cost-effectiveness study of three antimalarial drug combinations in Tanzania. PLoS Med. 2006:e373.
16. Guttmann P, Ehrlich P. Über die wirkung des methylenblau bei malaria. Berliner Klinische Wochenschrift. 1891:953-6.
17. Coleman MD, Coleman NA. Drug-induced methaemoglobinaemia. Treatment issues. Drug Saf. 1996:394-405.
18. Buchholz K, Schirmer RH, Eubel JK, et al. Interactions of methylene blue with human disulfide reductases and their orthologues from plasmodium falciparum. Antimicrob Agents Chemother. 2008:183-91.
19. Schirmer RH. Medikamente für die Armen. Spektrum der Wissenschaft. 2004:110-3.
20. Schirmer RH, Coulibaly B, Schiek W, et al. Methylene blue in the treatment of malaria-past and presence. Redox Report. 2003:272-6.
21. Coulibaly B, Zoungrana A, Mockenhaupt FP, et al. Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial. PLoS ONE. 2009:e5318.
22. Meissner P, Mandi G, Coulibaly B, et al. Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malaria J. 2006:84.
23. Mandi G, Witte S, Meissner P, et al. Safety of the combination of chloroquine and methylene blue in healthy adult men with g6PD deficiency from rural Burkina Faso. Trop Med Int Health. 2005:32-8.
24. Meissner P, Mandi G, Coulibaly B, et al. Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malaria J. 2006:84.
25. Zoungrana A, Coulibaly B, Sié A, et al. Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. PLoS One. 2008:e1630.
26. Kilama W, Ntoumi F. Malaria: a research agenda for the eradication era. Lancet. 2009:1480-2.
27. Coulibaly B, Zoungrana A, Mockenhaupt FP, et al. Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial. PLoS ONE. 2009:5318.
28. Bozdech Z, Llinas M, Pulliam B, Wong E, Zhu J, DeRisi J. The transcriptome of the intraerythrocytic developmental cycle of plasmodium falciparum. PLoS Biol. 2003:5.
29. Atamna H, Krugliak M, Shalmiev G, Deharo E, Pescarmona G, Ginsburg H. Mode of anti malarial effect of methylene blue and some of its analogues on plasmodium falciparum in culture and their inhibition of P. vinckei petteri and P. yoelii nigeriensis in vivo. Biochem Pharmacol. 1996:693-700.
30. Schirmer RH, Coulibaly B, Stich A, et al. Methylene blue as an antimalarial agent. Redox Rep. 2003:272-6.
31. Vennerstrom JL, Makler MT, Angerhofer CK, Williams JA. Antimalarial dyes revisited: xan-thenes, azines, oxazines, and thiazines. Antimicrob Agents Chemother. 1995:2671-7.
32. Liang C, Liebeke M, Schwarz R, et al. Staphylococcus aureus physiological growth limitations: insights from flux calculations built on proteomics and external metabolite data. Proteomics. 2011:1915-35.
33. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001:45.
34. Kanehisa M, Araki M, Goto S, et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res. 2008:480-4.
35. Gerhard M. Biochemical pathways. Heidelberg, berlin: spektrum akademischer verlag GmbH; 1999:99-107.
36. Aurrecoechea C, Brestelli J, Brunk BP, et al. PlasmoDB: a functional genomic database for malaria parasites. Nucleic Acids Res. 2008:539-43.
37. Papin JA, Price ND, Palsson BO. Extreme pathway lengths and reaction participation in genome-scale metabolic networks. Genome Research. 2002:1889-900.
38. Larhlimi A, Bockmayr A. A new constraint-based description of the steady-state flux cone of metabolic networks. Discrete Applied Mathematics. 2009:2257-66.
39. Llinás M, Bozdech Z, Wong ED, Adai AT, DeRisi JL: Comparative whole genome transcriptome analysis of three plasmodium falciparum strains. Nucleic Acids Research. 2006:1166-73.
40. R Development Core Team. R: A language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria 2006. Available at: http://www.r-project.org/.
41. Cecil A, Rikanović C, Ohlsen K, et al. Modeling antibiotic and cytotoxic effects of the dimeric isoquinoline IQ-143 on metabolism and its regulation in staphylococcus aureus, staphylococcus epidermidis and human cells. Genome Biol. 2011:24.
42. Schirmer RH, Coulibaly B, Stich A, et al. Methylene blue as an antimalarial agent. Redox Rep. 2003:272-6.
43. Vennerstrom JL, Makler MT, Angerhofer CK, Williams JA. Antimalarial dyes revisited: xanthenes, azines, oxazines, and thiazines. Antimicrob Agents Chemother. 1995:2671-7.
44. Krauth-Siegel RL, Bauer H, Schirmer RH. Dithiol proteins as guardians of the intracellular redox milieu in parasites: oldand new drug targets in trypanosomes and malaria-causing plasmodia. Angew Chem Int Ed Engl. 2005:690-715.
45. Becker K, Rahlfs S, Nickel C, Schirmer RH. Glutathione-functions and metabolism in the malarial parasite plasmodium falciparum. Biol Chem. 2003:551-66.
46. Becker K, Tilley L, Vennerstrom JL, Roberts D, Rogerson S, Ginsburg H. Oxidative stress in malaria parasite-infected erythrocytes: host-parasite interactions. Int J Parasitol. 2004:163-89.
47. Ferreira C. Sur l'emploi du bleu de méthylène dans la malaria infantile. Rev Ther Med Chir. 1893:488-525.
48. Ehrlich P. Chemotherapeutics: scientific principles, methods, and results. Lancet. 1913:445-51.